BioMark Diagnostics Return on Equity

BioMark Diagnostics (BMKDF) currently reports a ROE of -249.56%. That is below the sector sector average of 11.85%. Use the charts on this page to explore BioMark Diagnostics's ROE history and peer comparisons.

BioMark Diagnostics's ROE of -249.56% is lower than the its sector sector average of 11.85%. That is roughly 2205.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but BioMark Diagnostics's current -249.56% should be judged against industry norms (sector average: 11.85%) and against BMKDF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -249.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.85%. From there, open related valuation or income-statement pages for BioMark Diagnostics, and consider following BMKDF for alerts when major investors trade the stock.